Background -Hypersensitivity reactions to Malassezia spp have been shown to occur in dogs with atopic dermatitis (AD) and to cause exacerbation of clinical signs. Improvement of clinical signs following use of antifungal medication is seen with both Malassezia overgrowth or Malassezia hypersensitivity (MHS). Subcutaneous immunotherapy (SCIT) is considered a safe and effective treatment for management of canine AD. Adverse effects are considered rare.
Introduction
Malassezia pachydermatis is a lipophilic nonlipid-dependent yeast, that colonizes skin and mucosa of healthy dogs. It forms part of the normal microflora, but may under certain conditions act as a pathogen. 1 Malassezia spp. play multiple roles in the pathogenesis of human atopic dermatitis (AD). Malassezia dermatitis and immunoglobulin E (IgE)-mediated hypersensitivity to Malassezia spp may cause exacerbation of clinical signs. [2] [3] [4] Hypersensitivity to Malassezia pachydermatis also occurs in atopic dogs; hereafter designated as MHS. [5] [6] [7] [8] [9] Improvement of clinical signs following use of antifungal medication is seen in both human and canine atopic individuals. [10] [11] [12] [13] Allergen-specific immunotherapy (ASIT) is considered a safe and effective treatment of canine atopic dermatitis (CAD). Efficacy of 50-100% is reported in open uncontrolled studies. 14, 15 Adverse reactions are rare, but include pruritus, anxiety, hyperactivity and anaphylaxis. 15 Good response to ASIT in Malassezia-sensitized dogs has been reported anecdotally, but to best of the authors' knowledge, no clinical studies reporting on the efficacy and safety of such treatment have been published to date. 16 The aim of this retrospective study was to report the clinical response and adverse effects of subcutaneous immunotherapy (SCIT) with Malassezia extract in atopic dogs, mono-sensitized to Malassezia.
Materials and methods
Records from two practices were searched, between January 2011 and May 2016, for dogs treated with SCIT containing Malassezia extract only. All dogs had a clinical diagnosis of AD based on published criteria. 17 Ectoparasites had been ruled out. All dogs had undergone an eight week strict dietary trial, followed by a dietary rechallenge. Dogs diagnosed with food-induced atopic dermatitis (FIAD) were included in the study if strict adherence to diet had been shown to be insufficient to control clinical signs, and FIAD was considered well controlled. Additionally, all included dogs were deemed to be mono-sensitized to Malassezia based on positive reactions on intradermal testing (ArtuvetrinâTest, 100 lg/mL, ArtuVet Animal Health BV; Lelystad, Netherlands) and treated with SCIT with Malassezia extract (Artuvetrinâ, 100 lg/mL, ArtuVet Animal Health BV) 1 mL per month or dose-adjusted based on clinical response, for a minimum of 10 months. Exclusion criteria were uncontrolled adverse food reactions and dogs with multiple positive intradermal test reactions.
Records were assessed for evidence of Malassezia dermatitis (MD) and otitis (MO). Diagnosis was based on clinical examination and presence of Malassezia spp. on cytological evaluation, more than five organisms per high-power field (HPF) for skin and >10 per HPF for ears.
Clinical response to antifungal and anti-inflammatory therapy was recorded before and after at least 10 months of SCIT. Dogs were considered to show a good response to SCIT if the use of antifungal and anti-inflammatory drug dosages and frequency were reduced by ≥50%. Additionally, if dogs, according to records, were nonpruritic or had the same level of pruritus after 10 months of SCIT, they were considered responsive and nonresponsive, respectively. If this was not stated in the records, the owner was contacted and asked to estimate the pruritus pre-and post-SCIT, from a pruritus Visual Analog Scale (PVAS). If the decrease of pruritus was ≥50%, the dog was considered to have responded to SCIT.
Results

Signalment and clinical data
The search identified 16 cases fulfilling the inclusion criteria. Sex, breed and ages are reported in Table 1 . Four dogs were diagnosed with FIAD in addition to MHS. The mean age when starting SCIT was two years (range 1-6 years).
Status and therapy prior to SCIT Malassezia otitis had previously been diagnosed in 12 of 16 dogs; 13 of 16 dogs had been diagnosed with MD. For two dogs (cases 4 and 15) there was no recorded cytological evidence consistent with MO or MD ( Table 1) .
Monotherapy using an antifungal shampoo showed good response in three of four dogs (cases 3, 5 and 15). Response to combined topical antifungal shampoo and anti-inflammatory medication was recorded in 14 of 16 cases. Case 12 responded to topical anti-inflammatory treatment solely. Case 4 did not respond to topical treatment (Table 1) . No dogs received systemic antifungal therapies prior to SCIT.
Response to SCIT Good response to SCIT was seen in nine of 16 cases (56%), with a ≥50% reduction in antifungal treatment and anti-inflammatory medication (Appendix S1). All owners reported a decrease in pruritus of ≥50%.
Poor response was seen in seven of 16 cases. Increased use of anti-inflammatory treatment was noted in three of seven cases (4, 6 and 12) and systemic antifungal maintenance treatment was added in Case 6. Of the cases with limited response to treatment, two of seven owners had continued SCIT (cases 2 and 12). Case 4 showed, following discontinuation of SCIT, a marked increase in pruritus within three months. No change in pruritus was noticed in the others.
In three dogs (cases 1, 3 and 6) the dose of SCIT had been adjusted to 1 mL every three weeks, 1 mL every three weeks and 0.8 mL every three weeks, respectively. No adverse effects were recorded. Dogs responsive to SCIT were maintained on the treatment.
Pruritus scores pre-and post-SCIT are given in Appendix S1.
Discussion
In this study, nine of 16 dogs showed a good response to SCIT with Malassezia extract based upon a reduction in pruritus, and a reduction of concurrent topical and systemic antifungal treatment by ≥50%. Although the number of dogs fulfilling the inclusion criteria in this study is low, the results indicate that the efficacy of SCIT with Malassezia extracts corresponds well to the results of previous studies of immunotherapy using environmental allergens. 14, 15 Malassezia spp. are considered to be part of the normal flora of the skin and mucous membranes. Reduction of yeast can be achieved temporarily using antifungal medication and this is a recognized treatment in animals with MHS. 1, [10] [11] [12] [13] In our study, three of four dogs responded to topical antifungal shampoo as monotherapy. Topical treatment is time-consuming and often difficult to maintain on a long-term basis for owners. Adverse effects from longterm management with systemic antifungal drugs, as well as selection of fungal strains resistant to antimicrobial drugs, are possible concerns over time. 18, 19 SCIT treatment allowed for a marked reduction of antifungal medication as well as anti-inflammatory treatment in the majority of cases in this study, reducing the risk of adverse effects from drugs as well as the need for topical treatment in management of MHS.
Seven cases were considered to be nonresponsive to SCIT. In Case 4, the owner discontinued immunotherapy after two years due to lack of improvement and as a reduction in anti-inflammatory medication had not been possible. However, within three months after discontinuing SCIT, the dog's condition deteriorated despite intensified therapy. It is possible that SCIT had some effect in this dog despite the perceived poor response. Most of the dogs which were unresponsive to SCIT responded to a combination of antifungal and anti-inflammatory therapy. It seems likely that other causes contributed to the clinical disease in these cases. Possible causes include a false positive IDT result in a dog with atopic-like dermatitis and additional unrecognized FIAD or environmental hypersensitivities. It is also currently unknown if dogs could develop auto-immunity to Malassezia allergen analogues as recognized in humans. 4 In a nonpeer-reviewed report on Malassezia immunotherapy, results were reported as good to excellent in dogs treated with weekly injections of aqueous immunotherapy. 16 Aluminium hydroxide (alum) is used as an adjuvant and a depot mediator in vaccines. Although aluminium promotes a Th2-response, unwanted in allergy therapy, the protective effect seems partly due to an enhanced allergen-specific IgG-production. 20, 21 In our study, we used alum-precipitated IT dosed as 1 mL subcutaneously every four weeks with dose adjustments in three cases. To the best of our knowledge, there are no studies comparing the efficacy of aqueous versus alumprecipitated IT in CAD. In humans, studies have failed to demonstrate differences in efficacy between various types of SCIT. 22, 23 Atopic dogs are often poly-sensitized and combined sensitization to Malassezia and environmental allergens are common. Further assessment of whether these dogs would benefit from the addition of Malassezia extract to their treatment protocol compared to only using environmental allergens is needed. Previous studies have shown that mould proteases affect pollen extracts when mixed in the same aqueous SCIT. 24 However, one study showed a low protease activity in Malassezia extracts. 25 It is currently unknown if mixing fungal and other allergens affects the clinical outcome.
A major disadvantage of this study is the retrospective uncontrolled format and that a limited number of dogs fitted the inclusion criteria. A blinded, randomized controlled study of ASIT for Malassezia hypersensitivity, recording both clinical response as measured, for example, by Canine Atopic Dermatitis Extent and Severity Index (CADESI) and PVAS, as well as serological changes in allergen-specific IgE and IgG, and changes in cytokines such as TGF-b and IL-10 reflecting immune tolerance, would be an interesting future study.
Based on the findings in this study, we conclude that SCIT appears to be a safe treatment for dogs with Malassezia hypersensitivity and that response to SCIT is similar to the effect reported using SCIT for dogs sensitized to other environmental allergens.
Supporting Information
Additional Supporting Information may be found in the online version of this article. Appendix S1. Treatment administered to dogs pre-and post-Malassezia immunotherapy; response to immunotherapy in terms of clinical lesions and pruritus scores. 
Resumen
Introducci on -Se ha demostrado que las reacciones de hipersensibilidad a Malassezia spp. ocurren en perros con dermatitis at opica (AD) y causan exacerbaci on de los signos cl ınicos. La mejora de los signos cl ınicos despu es del uso de medicaci on antif ungica se observa tanto con el crecimiento excesivo de Malassezia como con la hipersensibilidad a Malassezia (MHS). La inmunoterapia subcut anea espec ıfica al ergeno (SCIT) se considera un tratamiento seguro y eficaz para el tratamiento de la AD canina. Los efectos adversos se consideran raros. Objetivos -Informar acerca del uso de SCIT con extractos de Malassezia en perros mono-sensibilizados. Animales -Diecis eis perros de propietarios privados diagnosticados con MHS y tratados con SCIT. M etodos -Revisi on retrospectiva de los historiales m edicos de perros at opicos diagnosticados con MHS, mono-sensibilizados para los al ergenos de Malassezia seg un la prueba intrad ermica y tratados con SCIT durante m as de 10 meses. La eficacia se midi o por la disminuci on en el uso de medicaci on antiinflamatoria y antif ungica en ≥50% y la disminuci on en el prurito en ≥50% seg un la evaluaci on de los propietarios, usando una puntuaci on para prurito. Resultados -Se observ o una buena respuesta a SCIT en nueve de 16 casos (56%), con una reducci on en el uso de medicaci on antiinflamatoria y antif ungica, as ı como una reducci on en las puntuaciones de prurito ≥50%. No se observaron efectos adversos. Conclusi on -La inmunoterapia espec ıfica para al ergenos fue un tratamiento seguro para perros con hipersensibilidad a Malassezia. La eficacia de la inmunoterapia contra Malassezia corresponde bien con resultados de estudios previos de inmunoterapia para otros alergenos ambientales.
Zusammenfassung
Hintergrund -Es konnte gezeigt werden, dass Hypersensibilit€ atsreaktionen auf Malassezia spp. bei Hunden mit atopischer Dermatitis (AD) vorkommen und eine Verschlimmerung klinischer Symptome verursachen. Eine Verbesserung der klinischen Symptome nach der Verwendung von Antimykotika konnte
